We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fragment-Based Drug Discovery of Cofactor-Specific Inhibitors for p97
Webinar

Fragment-Based Drug Discovery of Cofactor-Specific Inhibitors for p97

Fragment-Based Drug Discovery of Cofactor-Specific Inhibitors for p97
Webinar

Fragment-Based Drug Discovery of Cofactor-Specific Inhibitors for p97

Sebastian Bothe
Sebastian Bothe
PostDoc, Department of Biochemistry, University of Wuerzburg, Germany
Dr Helge Schnerr
Dr Helge Schnerr
Global Campaign Manager, Sartorius
The AAA-ATPase p97 is an essential protein involved in numerous cellular processes and plays a key role in multiple aspects of protein homeostasis. Its functional diversity is mediated through the interaction with many distinct cofactors. Due to its significant role in regulating a variety of physiological responses, p97 has emerged as a potential therapeutic target. In this webinar, Sebastian Bothe from the University of W├╝rzburg will present a combined approach that exploits computer-based methods, including virtual screening of molecular databases and biochemical/biophysical techniques.

Accelerate your research with a field-upgradeable, label-free biomolecule analysis platform. Octet® systems have become indispensable analytical instruments enabling a broad range of application and workflow requirements. In his presentation, Dr Helge Schnerr, Global Campaign Manager at Sartorius will provide an overview of label-free biolayer interferometry (BLI) and its benefits.

Attend this webinar to learn more about: 

  • How to select potential candidates
  • The use of biolayer interferometry (BLI) for fragment screenings
  • Developing label-free assays for small molecule characterization
  • Optimizing the measurement of small molecule inhibitors
Advertisement